In summary, we propose that RNF187 inhibition, which subsequently facilitates P53 signaling and induces cell cycle arrest and apoptosis, could be a therapeutic target for patients with P53 wild-type breast cancer. This evidence concerns the gene RNF187 and breast carcinoma.